881 Knockdown of neuropilin-1 by third generation antisense oligonucleotides has strong antitumor activity that can be further increased by combination with immune checkpoint inhibitors

• Alfred Zippelius,
• Mélanie Buchi,
• Richard Klar,
• Julia Festag,
• Monika Schell,
• Sven Michel,
• Frank Jaschinski,
• Nicole Kirchhammer,
• Andre Maaske,
• Laura Fernandez Rodriguez,
• Stefanie Raith

Affiliations

Alfred Zippelius

Department of Medical Oncology, University Hospital Basel, Basel, Switzerland

Mélanie Buchi

Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland

Richard Klar

Secarna Pharmaceuticals GmbH & Co KG, Planegg Martinsried, Germany

Julia Festag

Secarna Pharmaceuticals GmbH & Co KG, Planegg Martinsried, Germany

Monika Schell

1Secarna Pharmaceuticals GmbH and Co. KG, Martinsried, Germany

Sven Michel

Secarna Pharmaceuticals GmbH & Co KG, Planegg Martinsried, Germany

Frank Jaschinski

Secarna Pharmaceuticals GmbH & Co KG, Planegg Martinsried, Germany

Nicole Kirchhammer

Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland

Andre Maaske

Secarna Pharmaceuticals GmbH & Co KG, Planegg Martinsried, Germany

Laura Fernandez Rodriguez

2University Hospital Basel, Basel, Switzerland

Stefanie Raith

1Secarna Pharmaceuticals GmbH and Co. KG, Martinsried, Germany